F. Hoffmann-La Roche Ltd: New data for Roche s Hemlibra reinforce safety profile in people with haemophilia A
IIIb
haemophilia
Hemlibra
1
STASEY is one of the largest open-label studies primarily assessing safety and tolerability of a medicine for people with
haemophilia
Hemlibra also continued to demonstrate effective bleed control with a high proportion of participants (82.6%) achieving zero treated bleeds
1
Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra (emicizumab), consistent with the phase III HAVEN clinical programme.
1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International
The Burden of Musculoskeletal Diseases in the United States (BMUS).
Third ed. 2014.
9. Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 Update.
Arch Phys Med Rehabil. 2021;102(1):115–131. doi:10.1016/j.apmr.2020.04.001
10. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies.
Semin Arthritis Rheum. 2015;44(5):531–541. doi:10.1016/j.semarthrit.2014.10.012
11. Leyland KM, Gates LS, Sanchez-Santos MT, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data.
Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
19 to be independent predictors for incident CVD. In response to the recent rise of CVDs in developing countries, the World Health Organization (WHO) has identified very cost-effective interventions that are applicable even in low-resource settings for prevention and control of CVDs.
Although the WHO predicts a rapid increase of CVDs in SSA by 2030, researchers perceive that CVDs are not a priority public health problem in the region.
21 This perception is undermining the existing burden of the problem in this continent. Despite CVDs continuing to devastate human survival through the premature deaths of its workforce in developing countries, the few studies in Ethiopia have been limited to cross-sectional studies, which alone are insufficient to assess the risk of incident cardiovascular events. Therefore, we determined the incidence and predictors of cardiovascular disease among diabetic patients, from 2012 to 2020.
, MD, PhD,
a maternalâfetal medicine fellow with McGovern Medical School at UTHealth in Houston, and colleagues noted that earlier studies were limited by missing data, including pregnancy status, and likely had “biased case ascertainment.” Reference: Harris AD, et al. Ann Intern Med. 2021;10.7326/M21-0974.
The current study utilized the Premier Healthcare Database, “which captures 20% of U.S. discharges in an automated fashion from electronic medical records and provides a complete list of all patients who were discharged from the participating hospitals,” Pineles
told Healio Primary Care.
“Thus, we are very unlikely to be missing patients, and the data are robust,” she added.